Harvard Bioscience, Inc.

HBIO

US4169061052

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
3.26 ^USD	-0.61%		+19.85%	-39.07%

Jul. 01	Harvard Bioscience, Inc.(NasdaqGM:HBIO) added to Russell Small Cap Comp Value Index	CI
Jul. 01	Harvard Bioscience, Inc.(NasdaqGM:HBIO) added to Russell 3000E Value Index	CI

Harvard Bioscience, Inc. Announces the Resignation of Robert E. Gagnon, Chief Financial Officer, Effective August 31, 2018

August 22, 2018 at 08:35 am EDT

Harvard Bioscience, Inc. announced the resignation of Robert E. Gagnon, Chief Financial Officer, effective August 31, 2018. The Company has initiated a search for its next chief financial officer.

Latest news about Harvard Bioscience, Inc.

Harvard Bioscience, Inc.(NasdaqGM:HBIO) added to Russell Small Cap Comp Value Index	Jun. 30	CI
Harvard Bioscience, Inc.(NasdaqGM:HBIO) added to Russell 3000E Value Index	Jun. 30	CI
Harvard Bioscience, Inc.(NasdaqGM:HBIO) added to Russell 2500 Value Index	Jun. 30	CI
Harvard Bioscience, Inc.(NasdaqGM:HBIO) added to Russell 3000 Value Index	Jun. 30	CI
Harvard Bioscience, Inc.(NasdaqGM:HBIO) added to Russell 2000 Value Index	Jun. 30	CI
Harvard Bioscience, Inc.(NasdaqGM:HBIO) added to Russell Microcap Value Index	Jun. 30	CI
Transcript : Harvard Bioscience, Inc., Q1 2024 Earnings Call, May 07, 2024	May. 07
Earnings Flash (HBIO) HARVARD BIOSCIENCE Posts Q1 Revenue $24.5M	May. 07	MT
Earnings Flash (HBIO) HARVARD BIOSCIENCE Posts Q1 EPS $0.02	May. 07	MT
Harvard Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Harvard Bioscience, Inc. Provides Earnings Guidance for the Full Year 2024	May. 07	CI
Harvard Bioscience Reducing Headcount	Apr. 09	MT
Harvard Bioscience, Inc. Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth	Apr. 09	CI
Harvard Bioscience, Inc. Enters into A Third Amendment to the Credit Agreement	Apr. 03	CI
Transcript : Harvard Bioscience, Inc., Q4 2023 Earnings Call, Mar 07, 2024	Mar. 07
Earnings Flash (HBIO) HARVARD BIOSCIENCE Reports Q4 Revenue $28.2M	Mar. 07	MT
Earnings Flash (HBIO) HARVARD BIOSCIENCE Reports Q4 EPS $0.04	Mar. 07	MT
Harvard Bioscience, Inc. Provides Revenue Guidance for the Full Year 2024	Mar. 07	CI
Harvard Bioscience, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 07	CI
North American Morning Briefing : Powell Still in -2-	Mar. 07	DJ
Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications At Society of Toxicology Meeting	Mar. 06	CI
Transcript : Harvard Bioscience, Inc., Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07
Earnings Flash (HBIO) HARVARD BIOSCIENCE Reports Q3 Revenue $25.4M	Nov. 07	MT
Earnings Flash (HBIO) HARVARD BIOSCIENCE Reports Q3 EPS $0.01	Nov. 07	MT
HARVARD BIOSCIENCE INC - REMAIN ON PATH TO REDUCING NET LEVERAGE…	Nov. 07	RE

Chart Harvard Bioscience, Inc.

Duration

Period

More charts

Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Its products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. The CMT product family is primarily composed of products supporting research related to molecular, cellular, organ and organoid technologies. The Preclinical product family includes products that support the preclinical research and testing phase for drug development, and in particular, testing related to data collection and analysis for safety and regulatory compliance.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Harvard Bioscience, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.26 USD

Average target price

7 USD

Spread / Average Target

+114.72%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
HARVARD BIOSCIENCE, INC.	-39.07%	142M
THERMO FISHER SCIENTIFIC	+3.26%	209B
DANAHER CORPORATION	+6.55%	183B
INTUITIVE SURGICAL, INC.	+31.66%	158B
BOSTON SCIENTIFIC CORPORATION	+34.32%	114B
SIEMENS HEALTHINEERS AG	+5.13%	67.29B
EDWARDS LIFESCIENCES CORPORATION	+19.33%	54.83B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-3.30%	46.88B
AGILENT TECHNOLOGIES, INC.	-4.84%	38.58B
GE HEALTHCARE TECHNOLOGIES INC.	+3.83%	36.65B

Other Advanced Medical Equipment & Technology